What is the 13F Pro Quality Score for ANIP?

13F Pro ranks ANI PHARMACEUTICALS INC (ANIP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ANIP's current score at https://13fpro.ai/company/ANIP (free sign-up required for the full ranking).

Where does 13F Pro source ANIP data?

All ANI PHARMACEUTICALS INC fundamentals and ownership data come directly from SEC EDGAR. ANI PHARMACEUTICALS INC files with the SEC under CIK 1023024. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ANIP in?

ANI PHARMACEUTICALS INC (ANIP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives ANIP's revenue?

Per ANI PHARMACEUTICALS INC's latest 10-Q filed with the SEC on 2026-08-07, the biggest revenue drivers are: Rare Disease and Brands ($165.4M, +41.2% YoY); Generics and Other ($100.7M, +6.8% YoY); Cortrophin Gel ($117.1M, +43.5% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/ANIP.

What are ANIP's largest expenses?

ANI PHARMACEUTICALS INC's latest 10-Q reports these as the largest expense items: Cost of sales (excl. D&A) ($100.2M, +34.2% YoY); Selling, general, and administrative ($91.7M, +12.1% YoY); Depreciation and amortization ($19.6M, -15.6% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is ANIP research updated on 13F Pro?

ANIP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ANI PHARMACEUTICALS INC(ANIP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1023024 ANIP stock profile & AI dashboard →

13F Pro Quality Score

72.5/100

Rank #154 of 2,961 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

90.2/100

Profitability

74.3/100

Balance Sheet

79.6/100

Earnings Quality

80.0/100

Free Cash Flow

69.6/100

Institutional Flow

70.3/100

Revenue Scale

49.4/100

Dilution Risk

27.0/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ANIP Scores 73/100

exact factor attribution · 2026-09-11

ANIP's composite is driven by revenue growth and profitability, held back by shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.0 pts

90th pct

Profitability

+3.6 pts

74th pct

Earnings quality

+3.0 pts

80th pct

Capital efficiency

+3.0 pts

80th pct

Free cash flow

+2.9 pts

70th pct

Earnings growth

+2.1 pts

92th pct

Institutional flow

+1.0 pts

70th pct

Scale

-0.1 pts

49th pct

Shareholder dilution

-1.1 pts

27th pct

Latest change (2026-08-07): 69 → 68 · ↓ Revenue growth 89→78

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ANIP Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for ANI PHARMACEUTICALS INC (ANIP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ANIP at 72.5/100 on a 32-signal composite quality model, placing it at rank #154 of 2,961 stocks — the top 10% of the AI-ranked universe. ANIP scores in the top quartile across revenue growth (90.2), earnings quality (80.0), balance sheet strength (79.6). Shareholder dilution risk is elevated at 27.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ANI PHARMACEUTICALS INC reports quarterly revenue of $266.0M, net income of $24.7M, an operating margin of 15.2%. Top institutional holders of ANIP by reported 13-F value include BlackRock, Soleus Capital Management, L.P., VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ANIP trades on the Nasdaq exchange and files with the SEC under CIK 1023024. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANIP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ANI PHARMACEUTICALS INC directly from SEC EDGAR. ANI PHARMACEUTICALS INC's 13F Pro composite quality score has ranged between 24 and 75 since 2021, currently 72.5 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

What's Driving ANIP's Business? Latest 10-Q Breakdown

✓ 29/29 datapoints verified

AI-extracted from ANI PHARMACEUTICALS INC's 10-Q filed 2026-08-07 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

ANI Pharmaceuticals grew Q2 FY2026 net revenue 25.9% YoY to $266.0M, led by 43.5% growth in Cortrophin Gel and new Harmony Agreement royalties, driving operating income up to $40.5M from $13.9M a year ago.

Biggest Revenue Drivers

Rare Disease and Brands$165.4M+41.2% YoY

Driven by Cortrophin Gel volume growth and new Brand royalties/milestones under the Harmony Agreement

Generics and Other$100.7M+6.8% YoY

Driven by a partnered product launched in Q3 2025 and new generic product launches in 2026

Biggest Revenue Drivers

Total revenue: $266.0M+25.9% YoY

Rare Disease and Brands$165.4M+41.2% YoY

Driven by Cortrophin Gel volume growth and new Brand royalties/milestones under the Harmony Agreement

Within Rare Disease and Brands

Cortrophin Gel$117.1M+43.5% YoY

Increased volume from overall ACTH market growth and market share gains

ILUVIEN and YUTIQ$18.7M-16.1% YoY

No YUTIQ sales as the company transitioned U.S. promotion to ILUVIEN

Generics and Other$100.7M+6.8% YoY

Driven by a partnered product launched in Q3 2025 and new generic product launches in 2026

Largest Expense Items

Cost of sales (excl. D&A)$100.2M+34.2% YoY

Significant growth in sales volumes and growth of royalty-bearing products including Cortrophin Gel

Selling, general, and administrative$91.7M+12.1% YoY

Increased investment in Rare Disease sales and marketing infrastructure targeting acute gouty arthritis, tempered by lower legal costs

Depreciation and amortization$19.6M-15.6% YoY

Certain definite-lived intangibles became fully amortized during 2025

Research and development$14.7M-10.8% YoY

Timing of activity associated with ongoing and new projects supporting Rare Disease and Generics growth

Margins: Cost of sales rose to 37.6% of revenue from 35.3% YoY due to product mix shift toward royalty-bearing products, but operating margin still expanded to 15.2% from 6.6% as SG&A and D&A grew slower than revenue.

Watch Items from the Filing

Four customers each represented 10%+ of Q2 net revenues (24%, 14%, 12%, 9%), and three customers accounted for 56% of accounts receivable at June 30, 2026.
In the CG Oncology royalty litigation, a jury awarded ANI no damages and the court denied ANI's motions for a new trial in July 2026; ANI intends to appeal to the Delaware Supreme Court.
Novitium faces multiple new 2026 ANDA patent infringement suits (Harmony/AET-Sandoz, Orphalan, and Xeris/Strongbridge levoketoconazole litigation) that could affect generic product launches.
Approximately 23% of raw material inventory purchases in the period came from a single domestic supplier, concentrating supply risk.
Four unapproved products (EEMT, Opium Tincture, Thyroid Tablets, Hyoscyamine) generated $5.7 million of Q2 revenue despite lacking FDA-approved NDAs/ANDAs.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$266.0M

Net Income

Q2 2026

$24.7M

Free Cash Flow

Q2 2026

$53.6M

Operating Margin

Q2 2026

15.2%

ROIC

Q2 2026

18.0%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+43.8% YoY

$883.4MFY 2025

FY22 $316.4MFY23 $486.8MFY24 $614.4MFY25 $883.4M

Net Income

+522.9% YoY

$78.3MFY 2025

FY22 $-47.9MFY23 $18.8MFY24 $-18.5MFY25 $78.3M

Operating Income

+18922.8% YoY

$111.1MFY 2025

FY22 $-35.3MFY23 $47.0MFY24 $584.0KFY25 $111.1M

EPS (Diluted)

+419.2% YoY

$3.32FY 2025

FY22 $-3.05FY23 $0.85FY24 $-1.04FY25 $3.32

Total Assets

+12.2% YoY

$1.44BFY 2025

FY22 $760.1MFY23 $904.4MFY24 $1.28BFY25 $1.44B

Total Debt

-2.9% YoY

$309.1MFY 2025

FY22 $286.5MFY23 $285.7MFY24 $318.3MFY25 $309.1M

Op. Cash Flow

+189.3% YoY

$185.2MFY 2025

FY22 $-31.2MFY23 $119.0MFY24 $64.0MFY25 $185.2M

Free Cash Flow

+258.7% YoY

$171.4MFY 2025

FY22 $-40.1MFY23 $110.1MFY24 $47.8MFY25 $171.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$883.4M +43.8%	$614.4M +26.2%	$486.8M +53.9%	$316.4M +46.4%	$216.1M +3.7%	$208.5M
Net Income	$78.3M +522.9%	$-18.5M -198.6%	$18.8M +139.2%	$-47.9M -12.4%	$-42.6M -88.9%	$-22.5M
Operating Income	$111.1M +18922.8%	$584.0K -98.8%	$47.0M +233.1%	$-35.3M +11.3%	$-39.8M -148.5%	$-16.0M
EPS (Diluted)	$3.32 +419.2%	$-1.04 -222.4%	$0.85 +127.9%	$-3.05 +10.3%	$-3.40 -80.9%	$-1.88
Total Assets	$1.44B +12.2%	$1.28B +41.9%	$904.4M +19.0%	$760.1M -1.5%	$771.6M +67.3%	$461.2M
Total Debt	$309.1M -2.9%	$318.3M +11.4%	$285.7M -0.3%	$286.5M -0.3%	$287.4M +54.8%	$185.7M
Operating Cash Flow	$185.2M +189.3%	$64.0M -46.2%	$119.0M +481.2%	$-31.2M -1039.3%	$3.3M -78.2%	$15.3M
Free Cash Flow	$171.4M +258.7%	$47.8M -56.6%	$110.1M +374.7%	$-40.1M -5339.1%	$765.0K -91.6%	$9.1M

AI Insight: ANIP Financial Trends

ANI Pharmaceuticals swung to sustained profitability and 80% revenue growth since Q3 2024, while systematically deleveraging and building equity.

• Revenue grew 80% from $148M (Q3 2024) to $266M (Q2 2026); net income turned positive from -$24M loss to $25–$29M profit.

• Operating margin improved from -14% (Q3 2024) to +15% (Q2 2026); operating cash flow averaged $44M across trailing four quarters.

• Total debt declined $15M (5%) from $320M to $301M; equity grew $191M (47%) from $406M to $597M, improving financial flexibility.

⚠ Q2 2026 revenue of $266M exceeded Q1 2026 by $29M (12%), but operating cash flow dipped to $57M from prior quarter's $58M.

⚠ Net income stability: Q4 2025–Q2 2026 range $25–$29M suggests earnings plateau; monitor for growth acceleration.

AI Insight: ANIP Ratio Trends

ANIP swung from losses in late 2024 to sustained profitability and 18% ROIC by Q2 2026, while deleveraging steadily.

• Operating margin rebounded from –13.8% in Q3 2024 to 15.4% TTM; Q1–Q3 2025 averaged 11.6%, sustaining 14–16% into 2026.

• ROIC recovered from –11.3% (Q3 2024) to 18.0% in Q2 2026, indicating restored capital efficiency post-turnaround.

• Debt-to-equity fell from 0.79 (Q3–Q4 2024) to 0.50 (Q2 2026), reflecting leverage reduction and balance-sheet strengthening.

⚠ Q2 2026 NPM dipped to 9.3% from 12.4% in Q1 2026; monitor for seasonal volatility or margin pressure.

⚠ ROE and ROA moderated slightly Q1→Q2 2026 (21.0% to 16.6%, 8.3% to 6.6%); watch sustainability at current levels.

Get alerted when ANIP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ANI PHARMACEUTICALS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ANIP

BlackRock, Inc.
$244.9M2,958,646 sh
Soleus Capital Management, L.P.
$71.8M867,760 sh
VANGUARD CAPITAL MANAGEMENT LLC
$69.4M838,224 sh
STATE STREET CORP
$68.9M831,647 sh
Point72 Asset Management, L.P.
$62.0M47,850,000 sh
TANG CAPITAL MANAGEMENT LLC
$58.6M707,500 sh
DIMENSIONAL FUND ADVISORS LP
$51.6M623,463 sh
AMERICAN CENTURY COMPANIES INC
$47.6M574,474 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$46.5M562,016 sh
Global Alpha Capital Management Ltd.
$46.2M558,003 sh

Fund	Value	Shares
BlackRock, Inc.	$244.9M	2,958,646
Soleus Capital Management, L.P.	$71.8M	867,760
VANGUARD CAPITAL MANAGEMENT LLC	$69.4M	838,224
STATE STREET CORP	$68.9M	831,647
Point72 Asset Management, L.P.	$62.0M	47,850,000
TANG CAPITAL MANAGEMENT LLC	$58.6M	707,500
DIMENSIONAL FUND ADVISORS LP	$51.6M	623,463
AMERICAN CENTURY COMPANIES INC	$47.6M	574,474
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$46.5M	562,016
Global Alpha Capital Management Ltd.	$46.2M	558,003

Companies Similar to ANIP

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

COLL

COLLEGIUM PHARMACEUTICAL, INC

AI score

Similar quality profile · 25 shared holders

Rubric Capital Management LP LOOMIS SAYLES & CO L P Artemis Investment Management LLP

ARQT

Arcutis Biotherapeutics, Inc.

AI score

Similar quality profile · 14 shared holders

abrdn plc OBERWEIS ASSET MANAGEMENT INC/Rubric Capital Management LP

HRMY

Harmony Biosciences Holdings, Inc.

AI score

Similar quality profile · 26 shared holders

Bridge City Capital, LLC MARTINGALE ASSET MANAGEMENT L P Susquehanna Portfolio Strategies, LLC

AUPH

Aurinia Pharmaceuticals Inc.

AI score

Similar quality profile · 17 shared holders

TANG CAPITAL MANAGEMENT LLC PDT Partners, LLC SEGALL BRYANT & HAMILL, LLC

AMRX

Amneal Pharmaceuticals, Inc.

AI score

Similar quality profile · 20 shared holders

Rubric Capital Management LP Penn Capital Management Company, LLC Parkman Healthcare Partners LLC

HALO

HALOZYME THERAPEUTICS, INC.

AI score

Similar quality profile · 17 shared holders

Alberta Investment Management Corp KENNEDY CAPITAL MANAGEMENT LLC OBERWEIS ASSET MANAGEMENT INC/

GRDN

Guardian Pharmacy Services, Inc.

AI score

Similar quality profile · 16 shared holders

LOOMIS SAYLES & CO L P DRIEHAUS CAPITAL MANAGEMENT LLC Ranger Investment Management, L.P.

LIVN

LivaNova PLC

AI score

Similar quality profile · 28 shared holders

KENNEDY CAPITAL MANAGEMENT LLC OBERWEIS ASSET MANAGEMENT INC/Soleus Capital Management, L.P.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ANIP on your watchlist

Track score changes the day ANI PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ANIP a good stock to buy?

13F Pro's AI-powered analysis of ANI PHARMACEUTICALS INC (ANIP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ANIP are available on the ANIP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ANIP is classified as a small company.

Which hedge funds own ANIP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ANIP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ANI PHARMACEUTICALS INC's investment landscape.